# **Investor Presentation**

Interim Results 2020

# H1 2020 highlights


- Resilient performance in volatile market backdrop. Revenue performance +13.3% vs H1 2019
  - IB revenues -5.0%
  - Equities revenue +55.5%
- Strong performance by Equities led by strong trading profits<sup>(1)</sup> and higher execution revenues
- IB revenues impacted by weak equity capital market volumes due to pre-election uncertainty and COVID-19
- Improvement in Operating margin of 14.5% (FY 19: 12.6%)
- Interim dividend maintained at 5.5p against backdrop of widespread dividend suspensions
- Cash spend on share repurchases in the period total £5.5m (H1 2018: £7.5m)
- Strong balance sheet and liquidity position well positioned to support our corporate clients
- Good, near-term pipeline of secondary issuance for clients

# **Our response to COVID-19**


	Protecting employees	Serving clients	Short-term financial response
٠	All staff working from home since 13 March	<ul> <li>Maximised client engagement levels across the business</li> </ul>	<ul><li>Paused buyback programme for 6 weeks</li></ul>
٠	No staff furloughed and no redundancies	<ul> <li>Insightful research analysing impact</li> </ul>	<ul> <li>Reduced market risk</li> </ul>
	Staff wellbeing prioritised	<ul> <li>Facilitated institutional engagement with corporates</li> </ul>	<ul> <li>Strengthened liquidity position</li> </ul>
٠	Optimisation of remote working effectiveness	<ul> <li>Collaborative advice regarding</li> </ul>	<ul> <li>No Government support schemes accessed</li> </ul>
i	Well prepared for sustained	debt and equity solutions	<ul> <li>Stability to resume returns strategy and capitalise on growth</li> </ul>
	period of remote working	<ul> <li>Raised more than £600m in equity for clients since lockdown</li> </ul>	opportunities

## **H1 Market conditions**


### **Unfavourable market backdrop**



### UK ECM activity declined further against a weak comparative period<sup>(1)</sup>



### H1-20 Equity market performance<sup>(2)</sup>



- 6 month period featured significant market moves
- UK election result generated increase in equity market activity to the benefit of the Equities division
- Volatility levels dramatically increased in Feb & March
- COVID-19 significantly impacted the post-Election IB pipeline and restricting deal volumes
- Recovery in deal volumes will be led by balance sheet repair
- Investment portfolio valuations negatively impacted by market movements in the final weeks of the period



# **Income statement**

£'000	H1 2020	H1 2019	Change (%)
Revenue <sup>(1)</sup>	63,104	55,689	13.3%
Investment Income	(1,904)	(1,428)	(33.3%)
Staff costs <sup>(2)</sup>	36,999	30,200	22.5%
Non-staff costs	16,974	17,367	(2.3%)
Operating profit	7,227	6,694	8.0%
Underlying Operating profit	9,131	8,122	12.4%
PBT	7,257	7,108	2.1%
Net income	6,254	5,712	9.5%
EPS (pence)(3)	6.0p	5.4p	11.2%
Dividend (pence)	5.5p	5.5p	0.0%
Net Assets	136,672	140,221	(2.5%)
Cash and cash equivalents	95,332	78,876	20.9%
Underlying Operating profit margin	14.5%	14.6%	(0.1pp)



<sup>(1)</sup> Excluding losses on investment portfolio which is currently valued at £13m.
(2) Including share scheme charges and variable compensation provision for FY20
(3) Basic.

<sup>(4)</sup> Calculated as annualised net income / average net assets.


# **Performance summary**

H1 2020 in the context of recent historic performance

Revenue<sup>(1)</sup>








**Underlying Operating profit**(1)


Revenue per head





# Revenue analysis

### Revenue bridge H1 19 – H1 20



### Revenue bridge H2 19 - H1 20



### H1 20 Revenue analysis

£m	FY 20 H1	FY 19 H1	FY 19 H2	Change vs FY19 H1	Change vs FY19 H2
Total revenue	61.2	54.3	55.1	12.8%	11.0%
Capital markets	22.8	24.9	23.5	(8.1%)	(2.8%)
Advisory	7.2	7.5	5.0	(4.2%)	43.5%
Retainers	6.8	6.4	6.9	6.0%	(1.8%)
IB Revenue	36.9	38.8	35.5	(5.0%)	4.0%
Trading	6.5	0.4	3.6	n.m.	79.4%
Institutional income	19.7	16.5	16.8	19.2%	17.1%
Equities Revenue	26.2	16.9	20.5	55.5%	28.3%
Investment income	(1.9)	(1.4)	(0.8)	(33.3%)	(143.5%)

- Strong equities growth improved market activity levels and trading performance
- IB revenue ahead of H2'19 but impacted by lower deal volumes throughout a period impacted by political events and COVID-19
- Lower investment income due to unfavourable valuation movements of portfolio investments in line with market declines



# **Cost base analysis**


### **Costs analysis**

				Change vs Change vs	
Total costs £m	H1 2020	H2 2019	H1 2019	H1 19	H2 19
Staff costs	37.0	34.3	30.2	22.5%	7.7%
Non-staff costs	17.0	15.6	17.4	(2.3%)	8.2%
				(=:::/)	
Operating Margin %	14.5%	10.7%	14.6%	(0.1)ppts	3.8ppts


Headcount	Mar 2020	Sep 2019	Mar 2019
Period End	285	277	279
Average over 6m period	281	274	278

- Average headcount increased by 1% vs H1 2019
- Staff costs increase attributable to higher variable compensation provision due to the stronger revenue performance
- Non-staff costs are marginally lower than the comparative period
- Minimal impact from adoption of IFRS16 (c.£70k non-staff cost benefit)

### Staff costs



### Non-staff costs






# Dividends, buybacks and focus on shareholder returns






### Cash spend on dividends and share repurchases




### Share count (ISC net of treasury, inclusive of EBT)



- Dividend maintained despite unprecedented market conditions
- £5.5m spent on share repurchase during the period lower than comparative period
- Majority of vestings, and off-market purchases, occur in H1
- Intention to continue share repurchases to offset dilutive impact of share awards, subject to market conditions

# **Balance sheet and liquidity**

### Liquidity position remains strong – enhanced by new RCF





- Committed RCF provides further flexibility
- Significant capacity to provide underwriting support to clients

### Net asset progression (£m)




- Profitability offset by dividend in the period
- Reg cap cover maintained at c. 2x
- Ensures stability of the business and provides strategic flexibility
- 78% of NAV represented by cash and collateral (10% represented by Investment portfolio)

# **Investment Banking performance**


### IB revenue bridge H1 20 vs H1 19

# £38.8m £1.6m £1.6m (£5.8m) F1.6m (£1.6m) £38.8m £0.4m £36.9m £36.9m £36.9m £36.9m

### Further decline in client activity levels due to market backdrop



### Client base well position for any recovery in activity levels





- H1 20 revenue slightly below H1 19 and in line with H2 19 despite continued decline in ECM activity. No IPOs in H1
- Average deal fee improvement vs FY19
- Improvement in capital markets volumes expected in H2 as client activity increases in response to COVID-19
- M&A and Private markets pipeline adversely impacted in the near term

# **Equities income**


### Good trading performance in a volatile market







### Strongest institutional income performance since MIFID II introduction




- Institutional income 19.2% higher than H1 19 benefiting from an increase in market activity post the General Election, and thereafter COVID-19 related volatility
- Research payments remain in line with expectations
- Trading performance materially ahead of prior year which included the loss associated with the underwriting of Kier rights issue

# **Current trading and outlook**

- Capital markets transactions announced in recent weeks include Hyve, Polypipe, Foxtons and Asos
- Near term pipeline is encouraging predominantly recapitalisation deals
- M&A, IPO, and private markets have been impacted by COVID-19
- Equities has continued to perform in line with the strong first half
- Longer term outlook is difficult to forecast
- We will continues to protect our staff, support our clients, and ensure we are well positioned to take advantage of market opportunities arising from this period of disruption

# **Strategy overview**



# **Corporate client base**

FIG	ТМТ	Consumer	Building & Property (cont'd)	Natural Resources (cont'd)	Investment Companies	Investment Companies (cont'd)
3i Group plc	Technology	Retail	Building & Construction	Metals & Mining	Aberdeen Frontier Markets	Riverstone Energy Limited
AJ Bell	Accesso Technology	AO World	Balfour Beatty	Base Resources	Aberdeen New Thai	Schroder Asia Pacific Fund
Arbuthnot	Alfa Financial Software	ASOS	Bellway	Chaarat Gold	Acorn Income Fund	Schroder European REIT
Argentex	Allied Minds	B&M Europe	Bovis Homes	Danakali	Aquila European Renewables Income Fund	Schroder Oriental Income Fund
Arrow Global	AVEVA	H&T	Breedon	Ferrexpo	Baker Steel Resources Trust	Scottish Mortgage Investment Trust
Bank of Georgia	Draper Esprit	Lookers	Countryside Properties	Greatland Gold	Better Capital	Sherborne Investors B Ltd
Beazley	Emis	McColl's Retail Group	Forterra	Griffin Mining	Bluefield Solar Income Fund	Sherborne Investors C Ltd
Burford Capital	Keywords Studios	Mothercare	Foxtons	Highland Gold Mining	Catco Reinsurance	SME Credit Realisation Fund
Funding Circle Holdings	Learning Technologies	Motorpoint	Grafton	Horizonte Minerals	Custodian REIT	Stenprop
Hargreaves Lansdown	LoopUp	Ocado	Henry Boot	Pan African Resources	Edinburgh Worldwide	Third Point Offshore Investors
Hastings	Micro Focus International	Pets at Home	Howden Joinery	Shanta Gold	EJF Investments	Trian Investors 1
IG Group	Softcat	Superdry	Kier Group	Yellow Cake	EPE Special Opportunities	Troy Income & Growth
Intermediate Capital Group	ULS Technology		LSL Property Services		Fair Oaks Income Limited	TwentyFour Income Fund
International Personal Finance	Media	Travel and Leisure	Marshalls		Georgia Capital Plc	TwentyFour Select Monthly Income Fund
Jupiter Fund Management	Ascential	Domino's Pizza	Morgan Sindall	Healthcare	Henderson Smaller Companies	UK Mortgages Limited
Just Group	Auto Trader Group	Fuller Smith & Turner	Nexus Infrastructure	Abcam	HG Capital	VinaCapital Vietnam Opportunity
Lancashire Holdings	Centaur Holdings	The Gym Group	Norcros	Alliance Pharma	ICG Enterprise Trust	
Liontrust Asset Management	Ebiquity	Hostelworld	Polypipe	Benchmark Holdings	International Biotechnology Trust plc	Support Services
Mortgage Advice Bureau	Euromoney Institutional Investor	Marston's	Renew Holdings	Circassia Pharmaceuticals	International Public Partnerships	Biffa
Polar Capital Holdings	Future	On The Beach	Savills	Ergomed	JPMorgan Brazil Inv. Trust	Clipper Logistics
Premier Asset Management	Huntsworth		Tyman	e-Therapeutics	JPMorgan Claverhouse Inv. Trust	Diploma
Randall & Quilter	ITE Group	Other Consumer		Georgia Healthcare	JPMorgan Indian	Electrocomponents
River & Mercantile	Kin + Carta	Fever-Tree	Natural Resources	Horizon Discovery	JPMorgan Russian Securities	HSS Hire
Sabre Insurance	M&C Saatchi	Hilton Food Group	Oil & Gas	Induction Healthcare	JPMorgan US Smaller Cos	Knights plc
Saga	Next15	PureCircle	ADES International	IP Group	Jupiter UK Growth	JTC
	Ocean Outdoor	Stock Spirits	Genel Energy	MaxCyte	Keystone Investment Trust	Northgate
Industrials	Reach	Stock Spirits	Lekoil	Primary Health Properties	Menhaden Capital	Origin Enterprises
Capital Goods	Rightmove		Mycelx Technologies	Scapa	Miton Global Opportunities	RPS Group
Luceco	Wilmington	Building & Property	Nostrum Oil & Gas	Spire Healthcare	NB Global Floating Rate Income Fund	RWS
TT Electronics	YouGov	Real Estate	PetroTal	Syncona	Phoenix Spree Deutschland	Safe Harbour Holdings
Qinetiq	Telecoms	Capital & Regional	Savannah Petroleum	Vectura	Princess Private Equity	Wincanton
Chemicals	Telecom Plus	Grainger	Velocys		Raven Property	
Elementis		Helical	Vivo		RIT Capital Partners	
Synthomer		Palace Capital				
Wilmcote Holdings		St Modwen				
Other Industrials		Unite				
Accsys Technologies						

